Pfizer says FDA OKs updated infection vaccine

Feb 24, 2010 By MATTHEW PERRONE , AP Business Writer

(AP) -- Pfizer says the Food and Drug Administration has approved an updated version of its best-selling infection vaccine for children.

Prevnar 13 is intended to reduce the risk of infection by 13 varieties of pneumococcal disease, which causes ear infections, meningitis and . The new vaccine adds protection against six additional varieties of bacterial infection compared with the current vaccine.

The vaccine, developed by Wyeth, is the first product to win FDA approval since Pfizer acquired Wyeth last year.

With sales of $2.7 billion in 2008, Prevnar was considered a key product in Pfizer's decision to purchase Wyeth for $68 billion.

Explore further: India's meth addiction grows as criminals tap chemical hub

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA reviews update to Pfizer vaccine for kids

Nov 16, 2009

(AP) -- Federal health officials on Monday questioned whether to approve an updated version of Pfizer's best-selling anti-infection vaccine for children, despite company studies that failed to meet certain goals.

Wyeth seeking approval for advanced infant vaccine

Mar 31, 2009

(AP) -- Drugmaker Wyeth on Tuesday sought U.S. approval to sell a new version of its blockbuster infant vaccine Prevnar that protects against more strains of a bacteria that causes pneumonia and other diseases.

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0